Your browser doesn't support javascript.
loading
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au, Lewis; Fendler, Annika; Shepherd, Scott T C; Rzeniewicz, Karolina; Cerrone, Maddalena; Byrne, Fiona; Carlyle, Eleanor; Edmonds, Kim; Del Rosario, Lyra; Shon, John; Haynes, Winston A; Ward, Barry; Shum, Ben; Gordon, William; Gerard, Camille L; Xie, Wenyi; Joharatnam-Hogan, Nalinie; Young, Kate; Pickering, Lisa; Furness, Andrew J S; Larkin, James; Harvey, Ruth; Kassiotis, George; Gandhi, Sonia; Swanton, Charles; Fribbens, Charlotte; Wilkinson, Katalin A; Wilkinson, Robert J; Lau, David K; Banerjee, Susana; Starling, Naureen; Chau, Ian; Turajlic, Samra.
Affiliation
  • Au L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Fendler A; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Shepherd STC; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Rzeniewicz K; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Cerrone M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Byrne F; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Carlyle E; Tuberculosis Laboratory, The Francis Crick Institute, London, UK.
  • Edmonds K; Department of Infectious Disease, Imperial College London, London, UK.
  • Del Rosario L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Shon J; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Haynes WA; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Ward B; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Shum B; Serimmune, Inc., Goleta, CA, USA.
  • Gordon W; Serimmune, Inc., Goleta, CA, USA.
  • Gerard CL; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Xie W; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Joharatnam-Hogan N; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Young K; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Pickering L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Furness AJS; Precision Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Larkin J; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
  • Harvey R; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Kassiotis G; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Gandhi S; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Swanton C; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
  • Fribbens C; Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
  • Wilkinson KA; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
  • Wilkinson RJ; Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK.
  • Lau DK; UCL Queen Square Institute of Neurology, Queen Square, London, UK.
  • Starling N; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
  • Chau I; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.
  • Turajlic S; Tuberculosis Laboratory, The Francis Crick Institute, London, UK.
Nat Med ; 27(8): 1362-1366, 2021 08.
Article in En | MEDLINE | ID: mdl-34040262
ABSTRACT
Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: Colorectal Neoplasms / Cytokine Release Syndrome / COVID-19 Vaccines Limits: Humans / Male Language: En Journal: Nat Med Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: Colorectal Neoplasms / Cytokine Release Syndrome / COVID-19 Vaccines Limits: Humans / Male Language: En Journal: Nat Med Year: 2021 Document type: Article